The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Survival benefit associated with the number of chemotherapy/biologic treatment lines in 5,129 metastatic colon cancer patients.
Nader Hanna
No relevant relationships to disclose
Corinne Woods
No relevant relationships to disclose
Zhiyuan Zheng
No relevant relationships to disclose
Ebere Onukwugha
Consultant or Advisory Role - Janssen
Honoraria - IMH Health
Research Funding - Amgen; Bayer
Brian S. Seal
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
C. Daniel Mullins
Consultant or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Novartis; Novo Nordisk; Pfizer
Honoraria - Celgene
Research Funding - Bayer; Pfizer